A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Publications
  • Sharing surveillance data: the value of colla...
Published on 20 Nov 2020
Share
Publication

Sharing surveillance data: the value of collaboration in curbing the next pandemic

Routine drug resistance surveillance is essential for monitoring and controlling the spread of diseases and has proven to be a critical element of addressing the COVID-19 pandemic. Routine surveillance is also a crucial element in controlling the rise of antimicrobial resistance. 

In this viewpoint, authors Francesca Chiara (Senior Advisor, Drug Resistant Infections Programme, Wellcome); Moska Hellamand (Researcher, Access to Medicine Foundation); and Margo Warren (Government Engagement and Policy Manager, Access to Medicine Foundation) make the case for pharmaceutical companies to share surveillance data sets publicly, including through the AMR Register. 

Explore further

Media

Covid-like pandemics cast shadow on developing medicines for children

Jyothi Datta of the Hindu Business Line reports on the Foundation's series of articles stressing the urgent need for new “child-friendly” treatments for HIV, malaria and TB, especially with the looming impact of COVID-19 and emerging drug resistance.
Media

COVID-19 Pandemic rattles already vulnerable antibiotics market

Jessica Davis Plüss of SWI swissinfo.ch looks at how the COVID-19 pandemic is impacting the antibiotics market. The Access to Medicine Foundation's Antimicrobial Resistance Benchmark is cited for its insights into R&D in the field, and Executive Director Jayasree K. Iyer is quoted in the article.
Best Practice

First company to share raw AMR surveillance data

Pfizer is the first company to share raw data on the spread of resistance so that third parties can explore the potential for further research.

Get in touch

Back to top |